JP2011519941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519941A5 JP2011519941A5 JP2011508584A JP2011508584A JP2011519941A5 JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5 JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011508584 A JP2011508584 A JP 2011508584A JP 2011519941 A5 JP2011519941 A5 JP 2011519941A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- compound
- formula
- cancer
- erbb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- -1 morpholino, piperidinyl Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC Chemical compound COCCOc1cc2c(Nc3cccc(C#C)c3)ncnc2cc1OCCOC AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5032208P | 2008-05-05 | 2008-05-05 | |
| US61/050,322 | 2008-05-05 | ||
| PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519941A JP2011519941A (ja) | 2011-07-14 |
| JP2011519941A5 true JP2011519941A5 (https=) | 2012-06-21 |
Family
ID=41257222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508584A Pending JP2011519941A (ja) | 2008-05-05 | 2009-05-05 | ｃＭＥＴおよびＡＸＬの阻害剤並びにＥｒｂＢ阻害剤を使用するガンの治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20090274693A1 (https=) |
| EP (1) | EP2274304A4 (https=) |
| JP (1) | JP2011519941A (https=) |
| KR (1) | KR20110004462A (https=) |
| CN (1) | CN102083824A (https=) |
| AR (1) | AR071631A1 (https=) |
| AU (1) | AU2009244453B2 (https=) |
| BR (1) | BRPI0912582A2 (https=) |
| CA (1) | CA2723699A1 (https=) |
| CL (1) | CL2009001063A1 (https=) |
| EA (1) | EA020779B1 (https=) |
| IL (1) | IL209057A0 (https=) |
| MX (1) | MX2010012101A (https=) |
| PE (1) | PE20091832A1 (https=) |
| SG (1) | SG190623A1 (https=) |
| TW (1) | TW201006829A (https=) |
| UY (1) | UY31800A (https=) |
| WO (1) | WO2009137429A1 (https=) |
| ZA (1) | ZA201007722B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| SG173014A1 (en) | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| TWI507205B (zh) | 2009-03-25 | 2015-11-11 | Genentech Inc | 抗ｆｇｆｒ３抗體及使用方法 |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| WO2011014457A1 (en) * | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
| WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MX358013B (es) * | 2009-11-13 | 2018-08-01 | Amgen Inc | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. |
| EP2593090B1 (en) | 2010-07-16 | 2021-10-13 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CA2812750C (en) | 2010-09-27 | 2020-10-06 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| EP2656077A1 (en) * | 2010-12-23 | 2013-10-30 | Nestec S.A. | Drug selection for malignant cancer therapy using antibody-based arrays |
| CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
| CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス， インク． | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| KR20140025496A (ko) * | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| GEP201606523B (en) | 2011-09-22 | 2016-08-10 | Exelixis Inc | Method for treating osteoporosis |
| DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
| EP2780338B1 (en) * | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RS55728B1 (sr) | 2012-01-31 | 2017-07-31 | Daiichi Sankyo Co Ltd | Derivat piridona |
| JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
| WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| AU2014232714B2 (en) | 2013-03-15 | 2018-07-19 | Exelixis, Inc. | Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| EP2981263B1 (en) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
| CN105899226B (zh) | 2013-10-14 | 2020-05-12 | 詹森生物科技公司 | 半胱氨酸工程化iii型纤连蛋白域结合分子 |
| CA2938818C (en) | 2014-02-04 | 2023-03-07 | Astellas Pharma Inc. | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
| KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| CA2944573C (en) * | 2014-04-03 | 2022-10-25 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| WO2016104617A1 (ja) | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
| CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
| RU2748549C2 (ru) | 2016-04-15 | 2021-05-26 | Экселиксис, Инк. | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата |
| JP2019527540A (ja) | 2016-06-21 | 2019-10-03 | ヤンセン バイオテツク，インコーポレーテツド | システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子 |
| CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| EP3575293B1 (en) | 2017-01-26 | 2021-03-10 | ONO Pharmaceutical Co., Ltd. | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide |
| HUE068810T2 (hu) | 2017-02-15 | 2025-01-28 | Taiho Pharmaceutical Co Ltd | Gyógyászati készítmény |
| MA50251A (fr) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co Ltd | Agent antitumoral et potentialisateur d'effet antitumoral |
| EP3695839A4 (en) | 2017-10-13 | 2021-07-14 | ONO Pharmaceutical Co., Ltd. | THERAPEUTIC AGENT WITH AXL INHIBITOR AS AN ACTIVE INGREDIENT FOR SOLID TUMORS |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| AU2020210863B2 (en) * | 2019-01-25 | 2025-10-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| TW202444365A (zh) | 2023-01-31 | 2024-11-16 | 漢達生技醫藥股份有限公司 | 改良之卡博替尼組合物及其使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
| PT2213661E (pt) * | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
| UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| WO2007081978A2 (en) * | 2006-01-11 | 2007-07-19 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor / c-met activity |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| CA2683559C (en) * | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| CN101743253B (zh) * | 2007-05-17 | 2013-05-08 | 健泰科生物技术公司 | 神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构 |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| EP3050566B1 (en) * | 2007-09-10 | 2018-11-28 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en not_active Ceased
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Ceased
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519941A5 (https=) | ||
| JP2021523159A5 (https=) | ||
| AR071631A1 (es) | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres | |
| RU2013143381A (ru) | Фармацевтически приемлемая соль (е)-n-[4-[[3-хлор-4-(2-пиридилметокси)фенил]амино]-3-циано-7-этокси-6-хинолил]3-[(2r)-1-метилпирролидин-2-ил]проп-2-енамида, способ ее получения и ее медицинское применение | |
| JP2009507909A5 (https=) | ||
| JP2012504628A5 (https=) | ||
| RU2018103454A (ru) | Соединения бензоксазепиноксазолидинонов и способы применения | |
| JP2018504418A5 (https=) | ||
| JP2008535902A5 (https=) | ||
| JP2014528433A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2014533284A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2014518544A5 (https=) | ||
| JP2017510661A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| JP2013520431A5 (https=) | ||
| RU2012139825A (ru) | Антагонисты неурегулина и применение их в лечении злокачественного новообразования | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2012520321A5 (https=) | ||
| JP2020534300A5 (https=) | ||
| JPWO2019214634A5 (https=) |